Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493129 · ClinicalTrials.gov registry record · Phase 2
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00493129: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00493129 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00493129, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
Primary Objective: 1\. To assess the response rate of ONTAK in Systemic Mastocytosis (SM) patients. Secondary Objectives: 1. To assess the safety of ONTAK in SM patients. 2. To evaluate the time to progression and duration of response following treatment with ONTAK.
Interventions
- DRUG Ontak (Denileukin Diftitox)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2004-07 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00493129
The ClinicalTrials.gov registry entry for NCT00493129 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ontak (Denileukin Diftitox) is the first listed.
NCT00493129 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00493129 about?
NCT00493129 is a clinical study titled "Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)". Primary Objective: 1\. To assess the response rate of ONTAK in Systemic Mastocytosis (SM) patients. Secondary Objectives: 1. To assess the safety of ONTAK in SM patients. 2. To evaluate the time to progression and duration of response following treatment with ONTAK.
What is the current status of trial NCT00493129?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2004-07. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00493129?
The interventions under investigation include: Ontak (Denileukin Diftitox) (DRUG).
Who is sponsoring clinical trial NCT00493129?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.